Share this post on:

product name Z-DEVD-FMK


Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-3 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. Intracerebroventricular injections of Z-DEVD-FMK improved function after LFP. Intraparenchymal infusion of Z-DEVD-FMK over several days after combined CCI and hypoxia reduced lesion size, although functional outcome was not significantly improved in this model.

Reference:  Eur J Immunol. 1998 Jan;28(1):296-304; J Neurosci. 1997 Oct 1;17(19):7415-24.



Molecular Weight (MW)

668.66
Formula

C30H41FN4O12
CAS No.

210344-95-9
Storage

-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)

DMSO: 100 mg/mL (149.55 mM)
Water: <1 mg/mL (slightly soluble or insoluble)
Ethanol: <1 mg/mL
Solubility (In vivo)

 
Chemical Name

L-Valinamide, N-[(phenylmethoxy)carbonyl]-L-α-aspartyl-L-α-glutamyl-N-[(1S)-3-fluoro-1-(2-methoxy-2-oxoethyl)-2-oxopropyl]-, 1,2-dimethyl ester

other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/1940486

Z-DEVD-FMK (1–200 μM) inhibits D4-GDI cleavage and apoptosis in a concentration-dependent manner. Z-DEVD-FMK reduces ceramide-induced cardiomyocyte death and significantly inhibits the activation of caspase 3. Z-DEVD-FMK (100 μM) blocks MPP+-induced increases in caspase-3 enzyme activity. Z-DEVD-FMK dose dependently blocks 6-OHDA-induced apoptotic cell death with IC50 of 18 μM.
In Vivo Z-DEVD-FMK, before and after injury, markedly reduces post-traumatic apoptosis, and significantly improved neurological recovery
Animal model Male Sprague Dawley rats with Brain trauma.
Formulation & Dosage DMSO; 160 ng; Intracerebroventricular administration
Reference [1] Rickers A, et al. Eur J Immunol. 1998, (1), 296-304.; [2] Yakovlev AG, et al. J Neurosci. 1997, 17(19), 7415-7424.

Vigabatrin